Abemaciclib

Definition

An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

Also known as 2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl), ABEMACICLIB, LY 2835219, LY-2835219, LY2835219, Verzenio — per NCIT

Also identified as

• ATC L01EF03 per RXNORM
• NCIT NCIT:C97660 per NCIT
• SCTID 761851004 per RXNORM
• SCTID 763501007 per RXNORM
• UNII 60UAB198HK per RXNORM

Indications